The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 430.00
Bid: 426.00
Ask: 433.00
Change: -2.00 (-0.46%)
Spread: 7.00 (1.643%)
Open: 430.00
High: 430.00
Low: 430.00
Prev. Close: 432.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquires full ownership of its joint venture

6 Jan 2017 07:00

RNS Number : 4919T
Zotefoams PLC
06 January 2017
 

Zotefoams plc

("Zotefoams" or "the Company")

 

Zotefoams acquires full ownership of its joint venture, Kunshan ZOTEK King Lai

 

 

6 January 2017 - Zotefoams, a world leader in cellular materials technology, today announces that the Company has acquired full ownership of its joint venture, Kunshan ZOTEK King Lai ("KZKL"), from King Lai Group ("King Lai").

 

Zotefoams originally entered into an agreement with China-based King Lai in March 2015 to manufacture and sell the Company's T-FIT® insulation products through the joint venture, KZKL. Under the terms of the original agreement, KZKL was owned 51% by Zotefoams and 49% by King Lai, with manufacturing to be located in King Lai's factory in Kunshan, China.

 

Manufacturing has now been established on a separate, purpose designed state-of-the-art plant in Kunshan, Jiangsu Province, China and, following the grant of a business license to KZKL in December 2016, Zotefoams acquired full control of this business. KZKL will supply Zotefoams' T-FIT® insulation products to service the exacting demands of the biotechnology, pharmaceutical and semiconductor industries globally, other than in North America where our long-established relationship with a local partner remains in place.

 

David Stirling, Group CEO of Zotefoams plc, said:

"With Kunshan ZOTEK King Lai now a wholly owned subsidiary Zotefoams is well placed to fully capitalise on the potential of T-FIT® clean-room products, while also giving us a platform to extend the range of products under the T-FIT® brand during 2017."

 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0)208 664 1600

David Stirling, Group CEO

Gary McGrath, Finance Director

FTI Consulting

+44 (0)203 727 1000

Victoria Foster Mitchell / Simon Conway

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces and sells lightweight AZOTE® polyolefin and ZOTEK® high-performance foams for diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®).

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
JVEMMGGMZKNGNZZ
Date   Source Headline
12th Jul 201710:19 amRNSDirector/PDMR Shareholding
3rd Jul 20174:35 pmRNSPrice Monitoring Extension
13th Jun 20177:00 amRNSDirector/PDMR Shareholding
5th Jun 20172:14 pmRNSDirector/PDMR Shareholding
1st Jun 20174:30 pmRNSDirector/PDMR Shareholding
31st May 20177:00 amRNSDirector/PDMR Shareholding
17th May 20177:00 amRNSTrading Update
12th May 201711:16 amRNSDirector/PDMR Shareholding
12th Apr 20173:34 pmRNSAnnual Report and Accounts and Notice of 2017 AGM
12th Apr 20173:24 pmRNSDirector/PDMR Shareholding
12th Apr 20171:55 pmRNSHolding(s) in Company
10th Apr 20174:02 pmRNSDirector/PDMR Shareholding
6th Apr 20172:27 pmRNSHolding(s) in Company
6th Apr 20172:25 pmRNSHolding(s) in Company
28th Mar 201711:36 amRNSDirector/PDMR Shareholding
27th Mar 201710:16 amRNSHolding(s) in Company
24th Mar 20173:33 pmRNSHolding(s) in Company
23rd Mar 201710:11 amRNSHolding(s) in Company
22nd Mar 20173:28 pmRNSHolding(s) in Company
14th Mar 20175:28 pmRNSDirector/PDMR Shareholding
14th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSCoveris using MuCell® technology
15th Feb 201710:46 amRNSDirector/PDMR Shareholding
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20176:27 pmRNSHolding(s) in Company
12th Jan 20179:36 amRNSDirector/PDMR Shareholding
11th Jan 201710:33 amRNSHolding(s) in Company
10th Jan 20175:34 pmRNSHolding(s) in Company
9th Jan 20177:00 amRNSTrading Update
6th Jan 20177:00 amRNSAppointment of Joint Broker
6th Jan 20177:00 amRNSAcquires full ownership of its joint venture
22nd Dec 20164:35 pmRNSPrice Monitoring Extension
13th Dec 20161:58 pmRNSDirector/PDMR Shareholding
24th Nov 20167:00 amRNSHolding(s) in Company
15th Nov 201612:40 pmRNSDirector/PDMR Shareholding
14th Nov 201610:30 amRNSDirector Declaration
28th Oct 20167:00 amRNSThird Quarter Trading Update
25th Oct 20164:40 pmRNSSecond Price Monitoring Extn
25th Oct 20164:35 pmRNSPrice Monitoring Extension
24th Oct 201612:07 pmRNSSecond Price Monitoring Extn
24th Oct 201612:02 pmRNSPrice Monitoring Extension
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20163:43 pmRNSHolding(s) in Company
18th Oct 201611:56 amRNSDirector/PDMR Shareholding
14th Oct 20164:35 pmRNSPrice Monitoring Extension
13th Oct 20164:35 pmRNSPrice Monitoring Extension
12th Oct 20165:56 pmRNSDirector/PDMR Shareholding
5th Oct 20164:29 pmRNSHolding(s) in Company
14th Sep 201611:16 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.